Samantha Xavier, MD
Ophthalmology · Ocoee, FLNPI 1316240690
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 136 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,100, 2.2 times the $947 reported in 2019.
Across 136 payments — averaging $47.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- Bausch & Lomb Americas Inc.$815
- Regeneron Healthcare Solutions, Inc.$635
- Glaukos Corporation$522
- Apellis Pharmaceuticals, Inc.$456
- AbbVie$319
- plus $2K from 18 others
Across 39 payments — averaging $10,032 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$188K
- Ocular Therapeutix, Inc.$90K
- Aerie Pharmaceuticals, Inc.$80K
- Regeneron$25K
- Astellas Pharma Global Development$8K
What the payments were for
- Food & beverage$6,41599%
- Education$931%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 23 | $1,435 |
| Bausch & Lomb Americas Inc. | 8 | $815 |
| Regeneron Healthcare Solutions, Inc. | 19 | $635 |
| Glaukos Corporation | 4 | $522 |
| Apellis Pharmaceuticals, Inc. | 19 | $456 |
| AbbVie(2 entities) | 6 | $319 |
| Alimera Sciences, Inc. | 6 | $296 |
| Novartis | 9 | $243 |
| Astellas Pharma US Inc | 11 | $221 |
| Harrow Eye, LLC | 7 | $218 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $216 |
| Rxsight Inc | 2 | $215 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $203 |
| Tarsus Pharmaceuticals, Inc. | 2 | $144 |
| Dompe US, Inc. | 1 | $93 |
| Mallinckrodt Hospital Products Inc. | 1 | $93 |
| Silk Road Medical, Inc. | 1 | $92 |
| Genentech USA, Inc. | 4 | $79 |
| Ocular Therapeutix, Inc. | 2 | $63 |
| Rayner Intraocular Lenses Limited | 1 | $42 |
| ANI Pharmaceuticals, Inc. | 2 | $40 |
| Oyster Point Pharma, Inc. | 2 | $30 |
| Coherus Oncology, Inc. | 1 | $21 |
| Notal Vision, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$723
- XIIDRA$623
- EYLEA$231
- ENVISTA$216
- KXL System$200
- Centurion$142
- Photrexa Viscous and Photrexa$142
- Unity$139
- Clareon$131
- AcrySof$130
- LUMIGAN$125
- ALPHAGAN P$125
- DURYSTA$125
- Syfovre$122
- XDEMVY$122
- iDose$120
- TRAVATAN Z$117
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$113
- Tecnis Symfony IOL$110
- Tecnis Symfony Toric IOL$110
How this compares
$6,508 in reported general payments places this provider in the 80th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EyleaAflibercept | 570 | $1,362,898 |
| Eylea HdAflibercept | 36 | $149,625 |
| SyfovrePegcetacoplan/Pf | 52 | $131,400 |
| VabysmoFaricimab-Svoa | 42 | $112,741 |
| IzervayAvacincaptad Pegol Sodium/Pf | 31 | $69,300 |
| RestasisCyclosporine | 54 | $68,975 |
| Ketorolac Tromethamine | 620 | $20,217 |
| XiidraLifitegrast | 13 | $19,338 |
| Prednisolone Acetate | 514 | $16,627 |
| Alphagan PBrimonidine Tartrate | 29 | $11,286 |
| Cyclosporine | 19 | $11,141 |
| LumiganBimatoprost | 18 | $9,805 |
| IlevroNepafenac | 21 | $9,516 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 392 | $5,360 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $5,093 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Regeneron Healthcare Solutions, Inc.Eylea, Eylea Hd | $635 | $1,512,523606 claims |
| Apellis Pharmaceuticals, Inc.Syfovre | $456 | $131,40052 claims |
| Genentech USA, Inc.Vabysmo | $79 | $112,74142 claims |
| AbbVieRestasis, Alphagan P, Lumigan, Combigan | $319 | $95,159115 claims |
| Astellas Pharma US IncIzervay | $221 | $69,30031 claims |
| Bausch & Lomb Americas Inc.Xiidra | $815 | $19,33813 claims |
| NovartisIlevro | $243 | $9,51621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Ocoee
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
- William TrattlerMiami$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.